

Frank I Tarazi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/880356/frank-i-tarazi-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

93
papers

4,251
citations

36
h-index

63
g-index

93
ext. papers

4,842
ext. citations

4.7
avg, IF

5.54
L-index

#	Paper	IF	Citations
93	Zinc deficiency and supplementation in autism spectrum disorder and Phelan-McDermid syndrome.. <i>Journal of Neuroscience Research</i> , 2022 ,	4.4	2
92	Novel antidepressant drugs: Beyond monoamine targets. <i>CNS Spectrums</i> , 2021 , 1-10	1.8	0
91	What's Love Got to do with it: Role of oxytocin in trauma, attachment and resilience. <i>Pharmacology & Therapeutics</i> , 2020 , 214, 107602	13.9	9
90	Vitamin D Supplementation Ameliorates Severity of Major Depressive Disorder. <i>Journal of Molecular Neuroscience</i> , 2020 , 70, 230-235	3.3	18
89	The role of dopamine D receptors in the mechanism of action of cariprazine. <i>CNS Spectrums</i> , 2020 , 25, 343-351	1.8	18
88	Vitamin D supplementation ameliorates severity of generalized anxiety disorder (GAD). <i>Metabolic Brain Disease</i> , 2019 , 34, 1781-1786	3.9	6
87	Pharmacotherapy of schizophrenia: toward a metabolomic-based approach. <i>CNS Spectrums</i> , 2019 , 24, 281-286	1.8	9
86	Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. <i>Expert Opinion on Drug Discovery</i> , 2019 , 14, 81-89	6.2	38
85	Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis. <i>Expert Opinion on Drug Discovery</i> , 2018 , 13, 103-110	6.2	23
84	Autism Spectrum Disorder: Classification, diagnosis and therapy. <i>Pharmacology & Therapeutics</i> , 2018 , 190, 91-104	13.9	128
83	Long-Term Effects of Iloperidone on Cerebral Serotonin and Adrenoceptor Subtypes. <i>Journal of Molecular Neuroscience</i> , 2018 , 66, 59-67	3.3	3
82	Long-term effects of iloperidone on cerebral dopamine receptor subtypes. <i>Synapse</i> , 2018 , 72, e22039	2.4	4
81	Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine. <i>CNS Spectrums</i> , 2017 , 22, 484-494	1.8	13
80	Clinical and therapeutic role of mentalization in schizophrenia-a review. <i>CNS Spectrums</i> , 2017 , 22, 450-462	3	3
79	Developmental effects of antipsychotic drugs on serotonin receptor subtypes. <i>Synapse</i> , 2017 , 71, e21988	1.4	1
78	Dopamine and Opioid receptor dysregulation in the brains of binge-eating female rats - possible relevance in the psychopathology and treatment of binge-eating disorder. <i>Journal of Psychopharmacology</i> , 2017 , 31, 770-783	4.6	14
77	Clinical management of restless legs syndrome in end-stage renal disease patients. <i>CNS Spectrums</i> , 2017 , 22, 14-21	1.8	5

76	Differential effects of vilazodone versus citalopram and paroxetine on sexual behaviors and serotonin transporter and receptors in male rats. <i>Psychopharmacology</i> , 2016 , 233, 1025-34	4.7	14
75	The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder. <i>Expert Opinion on Drug Discovery</i> , 2016 , 11, 515-23	6.2	41
74	Clinical management of negative symptoms of schizophrenia: An update. <i>Pharmacology & Therapeutics</i> , 2015 , 153, 135-47	13.9	42
73	Asperger's syndrome: diagnosis, comorbidity and therapy. <i>Expert Review of Neurotherapeutics</i> , 2015 , 15, 281-93	4.3	13
72	Gene-environment interaction in major depression: focus on experience-dependent biological systems. <i>Frontiers in Psychiatry</i> , 2015 , 6, 68	5	82
71	Effects of antidepressant drug exposure on gene expression in the developing cerebral cortex. <i>Synapse</i> , 2014 , 68, 209-20	2.4	7
70	Long-term effects of cariprazine exposure on dopamine receptor subtypes. <i>CNS Spectrums</i> , 2014 , 19, 268-77	1.8	83
69	The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania. <i>Expert Opinion on Drug Discovery</i> , 2013 , 8, 93-103	6.2	21
68	Bapineuzumab and solanezumab for Alzheimer's disease: is the amyloid cascade hypothesis still alive?. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 1075-84	5.4	83
67	The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia. <i>Expert Opinion on Drug Discovery</i> , 2013 , 8, 1297-307	6.2	17
66	Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. <i>Pharmacology & Therapeutics</i> , 2012 , 134, 8-25	13.9	153
65	A translational approach to evaluate the efficacy and safety of the novel AMPA receptor positive allosteric modulator org 26576 in adult attention-deficit/hyperactivity disorder. <i>Biological Psychiatry</i> , 2012 , 72, 971-7	7.9	31
64	New pyridobenzoxazepine derivatives derived from 5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5]benzoxazepine (JL13): chemical synthesis and pharmacological evaluation. <i>Journal of Medicinal Chemistry</i> , 2012 , 55, 1572-82	8.3	16
63	Iloperidone, asenapine and lurasidone: a primer on their current status. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 1911-22	4	102
62	Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder. <i>Synapse</i> , 2012 , 66, 522-32	2.4	36
61	Asenapine induces differential regional effects on serotonin receptor subtypes. <i>Journal of Psychopharmacology</i> , 2010 , 24, 341-8	4.6	32
60	Effects of repeated risperidone exposure on serotonin receptor subtypes in developing rats. <i>European Neuropsychopharmacology</i> , 2010 , 20, 187-94	1.2	33
59	Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors. <i>International Journal of Neuropsychopharmacology</i> , 2010 , 13, 405-10	5.8	16

58	The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action. <i>Pharmacology & Therapeutics</i> , 2010 , 126, 173-85	13.9	56
57	Alterations in dopamine and glutamate neurotransmission in tetrahydrobiopterin deficient spr-/mice: relevance to schizophrenia. <i>BMB Reports</i> , 2010 , 43, 593-8	5.5	17
56	Subchronic effects of phencyclidine on dopamine and serotonin receptors: implications for schizophrenia. <i>Journal of Molecular Neuroscience</i> , 2009 , 38, 227-35	3.3	30
55	Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain. <i>Synapse</i> , 2009 , 63, 413-20	2.4	30
54	Effects of risperidone on glutamate receptor subtypes in developing rat brain. <i>European Neuropsychopharmacology</i> , 2009 , 19, 77-84	1.2	35
53	Asenapine maleate: a new drug for the treatment of schizophrenia and bipolar mania. <i>Drugs of Today</i> , 2009 , 45, 865-76	2.5	21
52	Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selectivity. <i>Journal of Medicinal Chemistry</i> , 2008 , 51, 983-7	8.3	23
51	Differential regional and dose-related effects of asenapine on dopamine receptor subtypes. <i>Psychopharmacology</i> , 2008 , 198, 103-11	4.7	32
50	Synthesis and binding studies of 2-O- and 11-O-substituted N-alkylnoraporphines. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008 , 18, 3971-3	2.9	14
49	Development of SPECT imaging agents for the norepinephrine transporters: [¹²³ I]INER. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007 , 17, 533-7	2.9	21
48	R-(-)-N-alkyl-11-hydroxy-10-hydroxymethyl- and 10-methyl-aporphines as 5-HT _{1A} receptor ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007 , 17, 4128-30	2.9	12
47	Effects of prenatal stress on dopamine D2 receptor asymmetry in rat brain. <i>Synapse</i> , 2007 , 61, 459-62	2.4	24
46	Long-term effects of JL 13, a potential atypical antipsychotic, on ionotropic glutamate receptors. <i>Journal of Molecular Neuroscience</i> , 2007 , 32, 192-8	3.3	6
45	Effects of risperidone on dopamine receptor subtypes in developing rat brain. <i>European Neuropsychopharmacology</i> , 2007 , 17, 448-55	1.2	25
44	Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes. <i>Journal of Neuroscience Research</i> , 2006 , 84, 675-82	4.4	6
43	Repeated antipsychotic drug exposure in developing rats: dopamine receptor effects. <i>Synapse</i> , 2006 , 59, 92-100	2.4	34
42	Atomoxetine blocks motor hyperactivity in neonatal 6-hydroxydopamine-lesioned rats: implications for treatment of attention-deficit hyperactivity disorder. <i>International Journal of Neuropsychopharmacology</i> , 2005 , 8, 439-44	5.8	27
41	3,4-dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's disease. <i>Journal of Neuroscience</i> , 2005 , 25, 2132-7	6.6	146

40	Regulation of working memory by dopamine D4 receptor in rats. <i>Neuropsychopharmacology</i> , 2004 , 29, 1648-55	8.7	94
39	Enhanced expression of dopamine D(1) and glutamate NMDA receptors in dopamine D(4) receptor knockout mice. <i>Journal of Molecular Neuroscience</i> , 2004 , 22, 167-78	3.3	41
38	Early adoption modifies the effects of prenatal stress on dopamine and glutamate receptors in adult rat brain. <i>Journal of Neuroscience Research</i> , 2004 , 76, 488-96	4.4	67
37	Dopamine D4 receptors: beyond schizophrenia. <i>Journal of Receptor and Signal Transduction Research</i> , 2004 , 24, 131-47	2.6	53
36	Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003 , 306, 1145-51	4.7	71
35	Animal models of attention-deficit hyperactivity disorder. <i>Brain Research Reviews</i> , 2003 , 42, 1-21		173
34	Serotonin transporter binding increases in caudate-putamen and nucleus accumbens after neonatal 6-hydroxydopamine lesions in rats: implications for motor hyperactivity. <i>Developmental Brain Research</i> , 2002 , 137, 135-8		29
33	Plasticity of dopamine D4 receptors in rat forebrain: temporal association with motor hyperactivity following neonatal 6-hydroxydopamine lesioning. <i>Neuropsychopharmacology</i> , 2002 , 26, 625-33	8.7	38
32	Stereoselective effects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning. <i>Psychopharmacology</i> , 2002 , 160, 92-8	4.7	70
31	Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. <i>Psychopharmacology</i> , 2002 , 161, 263-70	4.7	77
30	Effects of dopamine D4 receptor-selective antagonists on motor hyperactivity in rats with neonatal 6-hydroxydopamine lesions. <i>Psychopharmacology</i> , 2002 , 161, 100-6	4.7	46
29	Long-term effects of prenatal stress on dopamine and glutamate receptors in adult rat brain. <i>Neurochemical Research</i> , 2002 , 27, 1525-33	4.6	148
28	Effects of norepinephrine and serotonin transporter inhibitors on hyperactivity induced by neonatal 6-hydroxydopamine lesioning in rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002 , 301, 1097-102	4.7	78
27	Effects of newer antipsychotics on extrapyramidal function. <i>CNS Drugs</i> , 2002 , 16, 23-45	6.7	206
26	Long-term effects of newer antipsychotic drugs on neuronal nitric oxide synthase in rat brain. <i>Nitric Oxide - Biology and Chemistry</i> , 2002 , 7, 297-300	5	30
25	Nigrostriatal dopaminergic denervation enhances dopamine D(4) receptor binding in rat caudate-putamen. <i>Pharmacology Biochemistry and Behavior</i> , 2001 , 69, 111-6	3.9	9
24	Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2001 , 297, 711-7	4.7	73
23	Effects of nigrostriatal dopamine denervation on ionotropic glutamate receptors in rat caudate-putamen. <i>Brain Research</i> , 2000 , 881, 69-72	3.7	8

22	Olanzapine, quetiapine, and risperidone: long-term effects on monoamine transporters in rat forebrain. <i>Neuroscience Letters</i> , 2000 , 287, 81-4	3.3	15
21	Comparative postnatal development of dopamine D(1), D(2) and D(4) receptors in rat forebrain. <i>International Journal of Developmental Neuroscience</i> , 2000 , 18, 29-37	2.7	267
20	Alkylation of rat dopamine transporters and blockade of dopamine uptake by EEDQ. <i>Neuropharmacology</i> , 2000 , 39, 2133-8	5.5	4
19	Brain dopamine D(4) receptors: basic and clinical status. <i>International Journal of Neuropsychopharmacology</i> , 1999 , 2, 41-58	5.8	30
18	Dopamine D4 receptors: significance for molecular psychiatry at the millennium. <i>Molecular Psychiatry</i> , 1999 , 4, 529-38	15.1	67
17	Effects of alkylating agents on dopamine D(3) receptors in rat brain: selective protection by dopamine. <i>Brain Research</i> , 1999 , 847, 32-7	3.7	18
16	Neuropharmacological assessment of potential dopamine D4 receptor-selective radioligands. <i>European Journal of Pharmacology</i> , 1999 , 367, 139-42	5.3	8
15	[3H]beta-CIT: a radioligand for dopamine transporters in rat brain tissue. <i>European Journal of Pharmacology</i> , 1999 , 385, 291-4	5.3	35
14	Regional localization of dopamine and ionotropic glutamate receptor subtypes in striatolimbic brain regions. <i>Journal of Neuroscience Research</i> , 1999 , 55, 401-10	4.4	38
13	Selective alkylation of dopamine D2 and D4 receptors in rat brain by N-(p-isothiocyanatophenethyl)piperone. <i>Neuroscience Letters</i> , 1999 , 274, 155-8	3.3	2
12	Effects of chronic treatment with typical and atypical antipsychotic drugs on the rat striatum. <i>Life Sciences</i> , 1999 , 64, 1595-602	6.8	19
11	Postnatal development of dopamine D1-like receptors in rat cortical and striatolimbic brain regions: An autoradiographic study. <i>Developmental Neuroscience</i> , 1999 , 21, 43-9	2.2	133
10	Postnatal development of dopamine D4-like receptors in rat forebrain regions: comparison with D2-like receptors. <i>Developmental Brain Research</i> , 1998 , 110, 227-33		102
9	Localization of ionotropic glutamate receptors in caudate-putamen and nucleus accumbens septi of rat brain: comparison of NMDA, AMPA, and kainate receptors. <i>Synapse</i> , 1998 , 30, 227-35	2.4	76
8	Medial prefrontal cortical D2 and striatolimbic D4 dopamine receptors: common targets for typical and atypical antipsychotic drugs. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1998 , 22, 693-707	5.5	22
7	Effects of hippocampal lesions on striatolimbic ionotropic glutamatergic receptors. <i>Neuroscience Letters</i> , 1998 , 250, 13-6	3.3	14
6	Postnatal development of dopamine and serotonin transporters in rat caudate-putamen and nucleus accumbens septi. <i>Neuroscience Letters</i> , 1998 , 254, 21-4	3.3	145
5	Localization of ionotropic glutamate receptors in caudate-putamen and nucleus accumbens septi of rat brain: Comparison of NMDA, AMPA, and kainate receptors 1998 , 30, 227		4

4	Regional distribution of dopamine D4 receptors in rat forebrain. <i>NeuroReport</i> , 1997 , 8, 3423-6	1.7	59
3	Long-term effects of S(+)-N-n-propylnorapomorphine compared with typical and atypical antipsychotics: differential increases of cerebrocortical D2-like and striatolimbic D4-like dopamine receptors. <i>Neuropsychopharmacology</i> , 1997 , 17, 186-96	8.7	44
2	Compounds selective for dopamine receptor subtypes. <i>Drug Discovery Today</i> , 1997 , 2, 333-340	8.8	80
1	Brain dopamine receptors: a primer on their current status, basic and clinical. <i>Harvard Review of Psychiatry</i> , 1996 , 3, 301-25	4.1	83